About Triastek
Triastek is a company based in Nanjing (China) founded in 2015 by Xiaoling Li and Senping Cheng. Triastek has raised $102.3 million across 4 funding rounds from investors including Zheng Xiaodong, Goldmine and Shanghai Guoxin Investment Development. Triastek operates in a competitive market with competitors including Nuclera Nucleics, CELLINK, Collplant, ROKIT Healthcare and Precise Bio, among others.
- Headquarter Nanjing, China
- Founders Xiaoling Li, Senping Cheng
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$102.3 M (USD)
in 4 rounds
-
Latest Funding Round
$20.4 M (USD), Series B
Sep 28, 2023
-
Investors
Goldmine
& 12 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Triastek
Unlock access to complete
Unlock access to complete
Funding Insights of Triastek
Triastek has successfully raised a total of $102.3M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $20.4 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Triastek
Triastek has secured backing from 13 investors, including angel, institutional, and venture fund investors. Prominent investors backing the company include Zheng Xiaodong, Goldmine and Shanghai Guoxin Investment Development.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are invested in by this venture capital firm.
|
Locked | Locked | Locked | |
|
Acquisitions are targeted by CPE as a private equity firm.
|
Locked | Locked | Locked | |
|
Medical industry focused VC firm
|
Locked | Locked | Locked |
Investor details for Triastek
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Triastek
Investment portfolio details for Triastek
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Triastek
Detailed financials for Triastek
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Triastek Comparisons
Peer comparison for Triastek
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Triastek
Triastek operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nuclera Nucleics, CELLINK, Collplant, ROKIT Healthcare and Precise Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Desktop bioprinter for genes and proteins production is developed.
|
|
| Locked | Locked | Locked |
3D bioprinters and bioinks are developed for research applications.
|
|
| Locked | Locked | Locked |
Plant-derived collagen is developed for tissue repair and 3D bioprinting.
|
|
| Locked | Locked | Locked |
4D bio-printer solutions for tissue regeneration are provided.
|
|
| Locked | Locked | Locked |
Developer of integrated 3D printing and tissue-engineering platform
|
Detailed competitors of Triastek
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Triastek
Complete news archive for Triastek
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Triastek
Triastek was founded in 2015 and raised its 1st funding round 3 years after it was founded.
Triastek is headquartered in Nanjing, China. It is registered at Nanjing, Jiangsu, China.
Senping Cheng is the current CEO of Triastek. They have also founded this company.
Triastek is a funded company, having raised a total of $102.3M across 4 funding rounds to date.
Triastek was founded in 2015 and is headquartered in Nanjing, China. Operations center on the pharmaceutical sector, where a 3D printing technology platform is provided for drug design. Development of 3D bioprinters and Melt Extrusion Deposition (MED) technology is emphasized for dosage form creation. Digital pharmaceutical product development is also supported through these innovations.
Triastek's top competitors include Nuclera Nucleics, Allevi and Collplant.
Triastek has 13 investors. Key investors include Zheng Xiaodong, Goldmine, Shanghai Guoxin Investment Development, Matrix Partners China, and CPE.